Cancer development is a multistage process that results from the step-wise acquisition of somatic alterations in diverse genes. Recent studies indicate that caveolin-1 expression correlates with the level of oncogenic transformation in NIH3T3 cells, suggesting that caveolin in caveolae may regulate normal cell proliferation. In order to better understand potential functions of caveolin-1 in cancer development, we have studied expression levels of caveolin-1 in human breast cancer cells, and have found that caveolin expression is signi®cantly reduced in human breast cancer cells compared with their normal mammary epithelial counterparts. When the caveolin cDNA linked to the CMV promoter is transfected into human mammary cancer cells having no detectable endogenous caveolin, overexpression of caveolin-1 resulted in substantial growth inhibition, as seen by the 50% decrease in growth rate and by *l5-fold reduction in colony formation in soft agar. In addition, characterization of caveolin-1 expression during cell cycle progression indicates that expression of a-caveolin-1 is regulated during cell cycle. Furthermore p53-de®cient cells showed a loss in caveolin expression. In summary, the overall expression patterns, its ability to inhibit tumor growth in culture, its regulation during the cell cycle, and the loss of expression in p53-de®cient cells all are consistent with an important growth regulating function for caveolin-1 in normal human mammary cells, that needs to be repressed in oncogenic transformation and tumor cell growth.
Introduction
Cancer development is a multistage process that results from the step-wise acquisition of somatic alterations which may involve the activation of oncogenes and/or the inactivation of tumor suppressor genes (reviewed in Sager, 1989; Weinberg, 1991; Bishop, 1995) . While considerable progress has been made in the identification of oncogenes and tumor suppressor genes which play an important role in the regulation of cell proliferation and dierentiation (reviewed in Levine et al., 1991; Hartwell and Kastan, 1994) , little is known of the change of molecular machinery arising from the process of cellular transformation. Comparisons between normal and neoplastic cells at the molecular level have provided a powerful tool for the determination of the important altered phenotypes that contribute directly to their neoplastic potential (Friend et al., 1986; Liotta et al., 1991; Lee et al., 1991; Lee, 1996; Miki et al., 1994) .
Vesicular transport plays a fundamental role in many cellular functions. Caveolae are specialized invaginated micro-domains of the plasma membrane present in most mammalian cell types. Recently, caveolae have been puri®ed for the ®rst time from plasma membranes, and have been found to be rich in a subset of plasmalemmal molecules including signaling molecules such as IP 3 receptors, G proteins, caveolin-1 and src-like kinases, but quite distinct from Tritoninsoluble GPI-anchored protein microdomains (Schnitzer et al., 1995a,b) . Caveolae may have a number of important cellular functions. As dynamic vesicular carriers, they bud directly from the plasma membranes to form free transport vesicles containing the necessary molecular machinery for directed docking and fusion to mediate the endocytosis and transcytosis of select macromolecules (reviewed in Schnitzer, 1993; Schnitzer et al., 1994) . They also have been implicated in signal transduction (Strosberg, 1991; Chang et al., 1994; Liu et al., 1997) . Caveolin-1/VIP21, a 22 kD protein, appears to be an integral part of the striated coat of caveolae structures (Rothberg et al., 1992; Dupree et al., 1993) . Its expression may correlate with the formation of caveolae (Fra et al., 1995) . Caveolin-1 can therefore serve as a marker for the organelle. Recently, a potential role for caveolin in cell transformation has been implicated (Koleske et al., 1995) . Caveolin-1 expression correlates with the level of oncogenic transformation in NIH3T3 cells (Koleske et al., 1995) , suggesting that caveolin in caveolae may have a role in the regulation of normal cell proliferation. It also has been shown to be a major substrate of v-src oncogene (Glenney and Soppet, 1992; Li and Lisanti, 1996) .
In order to understand the potential functions of caveolin-1 in cancer development, we have characterized the overexpression of caveolin and its eect on tumor growth in human mammary cancer cells. The evidence from this study that expression of caveolin-1 is signi®cantly reduced in human breast cancer cells compared with their normal mammary epithelial counterparts focuses interest on the regulatory mechanisms of cell growth. The studies presented here on cell cycle regulation, caveolin-1 re-expression and its resulting phenotypes, and its dierential expression in p53-null cells are aimed towards understanding a functional role of caveolin-1 in normal cell growth and carcinogenesis.
Results

Caveolin-1 expression in human normal and tumor mammary epithelial cells
Caveolin-1 mRNA and protein expression were examined in a series of normal mammary epithelial cells (NMEC) and tumor mammary epithelial cells (TMEC). Northern analysis revealed the expression of a major transcript, 3.0 kb, in the normal cells, but no or slight expression in the cancer cells (Figure 1a) . A major band, 3.0 kb in size, was abundantly expressed in normal cells (12N and 13N) and two immortalized mammary epithelial cell lines (184B5 and MCF10), but weak (21MT-1 and MDA435) or no expression was seen in series of human breast cancer cells (MCF7, ZR75, T47D, BT20, 21MT-1 and MDAMB435). Caveolin-1 protein expression was also measured in NMECs and TMECs by Western blot analysis. Western blot analysis revealed that protein expression was also signi®cantly reduced or absent in human mammary cancer cells compared to normal cells ( Figure 1b) . To examine the possibility of a deletion or gross rearrangement in the human caveolin-1 gene of tumor cells, genomic DNA from normal and tumor cells was digested with restriction enzymes (EcoRI, HindIII) and subjected to Southern blot analysis using a full-length human caveolin cDNA probe (Figure 1d , HindIII not shown). After hybridization, several fragments were detected in all digests, indicating that the caveolin gene is present in both normal and tumor cells without detectable gross rearrangement. Thus, the loss or reduction of caveolin-1 and its mRNA in tumor cells seems to result primarily from transcriptional regulation. Caveolin mRNA expression was also examined in a variety of dierent cell types (data not shown). MDCK epithelial cells derived from canine kidney, showed the highest expression of caveolin-1 compared with the other cells tested. A10, smooth muscle cells derived from rat thoracic aorta showed the lowest expression of caveolin-1 and are expected to express rather speci®cally caveolin-3 (Tang et al., 1996) . Caveolin-1 expression in BAEC, endothelial cells derived from bovine aorta, and BLMVEC, bovine lung microvascular endothelial cells seems relatively equal in their signal. This broad expression pattern of caveolin may imply an important functional role in many cell types.
Re-expression of caveolin in human breast cancer cells
To investigate a functional role of caveolin-1 in breast cancer development, transfection studies were performed using a full-length human caveolin-1 cDNA. To assess the impact of reexpressed caveolin on the malignant phenotype in human breast cancer cells, an established human mammary cancer cell line, T47D, which expresses no detectable basal levels of caveolin-1 (Figure 1a , b and c), was used for the transfection study with a mammalian expression vector (pcDNA3, Invitrogen Inc.) containing the human caveolin-1 fulllength cDNA under the control of the cytomegalovirus (CMV) promoter. The vector alone was used as a control. For each of the cell lines, 2 ± 3 weeks after G418 selection, individual G418-resistant and caveolin expressing cell clones were obtained. A total of ten Immunoblot analysis of caveolin-1 protein in NMECs, and TMECs. (c) Caveolin protein expression in caveolin-or control vector-transfected T47D TMEC. Aliquots of cell lysates derived from number of indicated cell lines were loaded in each of the lanes, and then separated by SDS ± PAGE, transferred to PDVF membrane, stained with Ponceau S to verify equal loading, and then immunoblotted with antibodies to caveolin and b-actin, respectively. The similar intensities seen for b-actin shows equal loading. (d) Southern blot analysis of human caveolin genomic DNA. Genomic DNA was isolated, digested with E coRI restriction enzyme, separated by 0.8% agarose gel electrophoresis, and transferred to a nylon membrane and hybridized with human caveolin cDNA T47D stable cell clones expressing caveolin were established. Ten control stable transfectants were also obtained. The initial clonal growth of caveolin-1 transfectants was several times slower than cells transfected with vector alone. As shown in Figure  1c , caveolin protein expression was now detected in T47D-caveolin transfectants (7S and 9S) but no expression was detected in control T47D transfectants (C9 and C11), as was observed in the parental T47D. b-actin was used as loading control. Using these established stable transfectants (two controls and two senses), we examined the eects of caveolin reexpression on the cell growth rate and on the tumorigenicity of the cells in vitro as measured by focus formation in a soft-agar clonogenic assay. The introduction of caveolin-1 cDNA expression resulted in substantial growth inhibition, as seen by the 50% decrease in growth rate (Figure 2 and by the 3 ± 10-fold reduction in colony formation in soft agarose ( Figure 3 ).
Cell cycle expression of caveolin in human NMEC
Because of the reduced expression in cancer cells and the eect on cell proliferation in caveolin-transfected cells, we assessed the relative periodicity of caveolin expression during the cell cycle of human normal breast cells. NMECs were synchronized in G 0 by growth factor starvation. Cells were sampled at 4 h intervals over 36 h, except for the ®rst sample at 2 h, and caveolin expression levels were analysed by Western blot analysis. Progression of the cells through the cell cycle was monitored by [ 3 H]thymidine incorporation and by the level of histone H4 and CDC2 mRNAs in Northern blot analysis (data not shown), and CDC2 and p53 protein in Western blot analysis (Figure 4) . b-actin was also used for a loading control. As shown in Figure 4 , a-caveolin-1 levels gradually increased during cell cycle progression and peaked during the G2/M phase, suggesting that acaveolin-1 has a distinct functional role which is dependent on the cell cycle.
Caveolin distribution in human NMEC and caveolintransfected cells
The expression of caveolin-1 and its ability to inhibit cell growth and colony formation of the caveolin-1 transfected cells led us to look for the localization of caveolin in these cells using immuno¯uorescence microscopy. T47D cells transfected with the vector alone (C9 and C11) showed little, if any, detectablē uorescence ( Figure 5a and b) , while the caveolin-1 transfected cells (7S and 9S) showed an appreciable signal (Figure 5c ± f). For 9S, the staining pattern for caveolin was primarily perinuclear which may represent Golgi labeling. For 7S the caveolin-1 found was primarily between adjacent cells with some Figure 5g shows normal mammary epithelial cells (12N) with stronger caveolin-1 staining found both in the perinuclear region and at the edge of the cells. The ability of caveolin-1 reexpression in 7S to inhibit growth and colony formation greater than that for 9S may be due to dierences in caveolin-1 localization. Caveolin-1 localization when found closer to the cell surface may enhance its ability to communicate via a signal pathway.
Caveolin-1 expression is altered in MEDF cells from p53 7/7 mice It is clear now that functional inactivation of p53 leads to a selective growth advantage and further to the development of human neoplasia (Harvey et al., 1994; Jacks et al., 1994) . In order to more closely de®ne whether the reduction or loss of caveolin expression in cancer cells may result from an oncogenic process, we measured the levels of caveolin-1 expression in mouse embryonic dermal ®broblasts (MEDF) isolated from p53 de®cient mice. In wild type cells, as expected, p53 protein was induced in response to the DNA damaging agent, mitomycin C (MMC), but no p53 induction showed in p53 7/7 MEDF cells ( Figure 6 ). The same blot was used to measure caveolin expression in both wild type and p53 de®cient MEDF. As shown in Figure 6 , caveolin was expressed in wild type MEDF cells but little caveolin protein was detected in p53
MEDF cells. This data suggest that The loss of caveolin expression in p53 7/7 MEDF suggests that caveolin-1 might be a critical target in the pathway leading to carcinogenesis.
Discussion
Caveolin is clearly found in caveolae on its inner surface (Schnitzer et al., 1995b; Rothberg et al., 1992; Dupree et al., 1993) and is also present as a major v-src substrate in Rous Sarcoma virus-transformed fibroblasts (Glenny and Soppet, 1992) . Caveolin-1 is one of two proteins which display the selective phosphorylation by v-src (Li and Lisanti, 1996) . The disruption of caveolae integrity appears to be a general feature of oncogenic transformation of ®broblasts (Glenny and Soppet, 1992; Koleske et al., 1995) . Furthermore, the levels of caveolin correlate with the degree of cellular transformation (Koleske et al., 1995) . Caveolin-1 expression was also one of many transcripts that were expressed at signi®cantly dierent levels in mammary normal and neoplastic cells, that were identi®ed by dierential screening (Sager et al., 1994) . In order to better understand potential functions of caveolin in cancer development, we have analysed the phenotypic consequences of caveolin over-expression in mammary cancer cells by transfection studies. Prior work has Figure 5 Immunolocalization of caveolin in NMEC (12N) and TMEC (T47D) transfected with vector alone (C9 and C11) or caveolin cDNA (7S and 9S). As in our past work (14), above cells were ®rst blocked with PBS containing 2% goat serum, then incubated with antibodies to caveolin (1:1000) for 2 h at room temperature, rinsed and labeled with anti-rabbit IgG conjugated to Biodipy (1:1000) for 1 h before ®nal rinse. β-Actin Figure 6 Caveolin expression in mouse embryonic dermal ®broblasts (MEDF) isolated from p53 de®cient or wild-type mice following mitomycin C (MMC) treatment. MEDF from p53 -/-or wild-type mice were treated with 20 mg/ml of MMC. Cells were harvested after initiation of treatment at times points over 24 h. All cells were collected and processed in SDS ± PAGE and Western analysis. The same blot was used to measure caveolin expression in both wild type and p53 de®cient MEDF. Caveolin was expressed in wild type MEDF cells but no caveolin protein was detected in p53 -/-MEDF cells. b-actin was used to verify equal loading of proteins suggested that oncogeneic transformation leads to reductions in cellular levels of caveolin, and that this reduction probably contributes to a loss of caveolae (Koleske et al., 1995) . The present study shows that the level of caveolin-1 is correlated with mammary cancer progression in vitro and the overexpression of caveolin-1 resulted in substantial growth inhibition of mammary tumor cells which normally have no endogenous caveolin expression. Our ®nding that caveolin-1 overexpression greatly reduces not only cell growth but also tumorigenicity in vitro is consistent with the oncogenic transformation of the cells being responsible for the lack of caveolin-1 expression and this transcriptional inhibition relating functionally to the tumor phenotype.
Caveolin-1 is derived from a single gene encoding one mRNA but creating two caveolin isoforms that dier by approximately 3 kDa (15 amino acids at Nterminus), termed a-and û-caveolin, respectively (Scherer et al., 1995; 1996) . Even though both isoforms are targeted to caveolae, form homooligomers, and interact with G proteins, the functional regulation or modi®cations such as phosphorylation levels seems dierent to each other. Furthermore, only a-caveolin is phosphorylated on serine residues in vivo (Scherer et al., 1995) . Our results also reveal the distinct expression patterns of the caveolin-1 isoforms during cell cycle progression. Only a-caveolin levels increased expression during cell cycle progression, suggesting that a-caveolin has a distinct role in a cell cycle dependent manner. Future studies need to be directed towards characterizing and determining whether caveolae formation can be generated in a cell cycle dependent manner. Interestingly, there have been several reports that endocytic structures such as noncoated and clathrin-coated plasmalemal vesicles are reduced signi®cantly with cell proliferation (Scherer et al., 1995) .
The introduction and overexpression of caveolin-1 in human breast cancer cells markedly decreased cell growth rates and resulted in a reduction of anchorageindependent growth in soft agar. This is the ®rst direct study by stable transfection experiments demonstrating that caveolin is involved in cell growth control in human cancer. In order to de®ne whether the reduction or loss of caveolin-1 expression in cancer cells may result from an oncogenic process, we measured the levels of caveolin expression in mouse embryonic dermal ®broblasts (MEDF) isolated from p53 deficient mice. The eect of p53 in tumor suppression is likely to be mediated by numerous as yet undiscovered p53 response genes whose expression is activated or repressed by p53-independent or -dependent mechanism. It is clear now that functional inactivation of p53 leads to selective growth advantage and further to the development of human neoplasia (Jacks et al., 1994) . Caveolin-1 is expressed in wild type MEDF cells as expected but little or no caveolin protein is detected in p53 7/7 MEDF cells. However, the introduction of wild-type p53 into a p53 null cells did not induce caveolin expression (data not shown), suggesting that caveolin is not directly regulated by p53. This loss of caveolin-1 expression in p53
MEDF cells still suggests that caveolin might be a critical target in the pathway leading to carcinogenesis, but it remains still unclear whether the loss of caveolin-1 levels in p53 null MEDF cells is a direct consequence of p53 inactivation. In addition, reductions in cellular levels of caveolin by oncogenic transformation (Koleske et al., 1995) are consistent to decreases of caveolin expression in p53 7/7 cells. This growth inhibition may explain why caveolae formation with virally infected caveolin-1 expression has only been reported under transient but not stable conditions (Fra et al., 1995) . In examining our caveolin-transfected neuroblastoma and epithelial carcinoma cells by electron microscopy, we unfortunately were not able to detect any caveolae. However, we did detect an apparent increase in small trans Golgi vesicles and some other larger vesicles near but not attached to the plasma membrane (our unpublished observations). It would appear that other factors which are absent or repressed in these tumor cells may be required along with caveolin-1 for the formation of caveolae at the cell surface. Alternatively, certain post translational modi®cations of caveolin-1 itself may be required for its ecient transport from the Golgi to the plasma membrane where caveolae formation could be induced. As the immuno¯uorescence showed ( Figure  5 ), some expression of caveolin-1 at or near the cell surface was observed. It is not clear whether a critical cell surface concentration is required for induction or whether additional factors or modi®cations of caveolin-1 are required for its oligomerization to form caveolae.
Interestingly, it is apparent that the level of caveolin-1 expression does not necessarily correlate with the cell surface density of caveolae. In fact, the MDCK cells have the fewest caveolae of cells examined with less than 0.1% of the cell surface being invaginated as caveolae. Of the cultured endothelial cells, the BLMVEC have the most caveolae with a density much greater than BAECs (Schnitzer et al., 1994) . Unfortunately even the caveolar density found in the BLMVEC is much less than seen in vivo in the natural milieu of the tissue rather than the arti®cial, imperfectly mimicking the environment of cell culture.
Because a stable transfected cell line would be quite useful in assessing caveolin function, especially under inducible conditions, more work addressing this problem is justi®ed. Our original interest, when we began the transfection studies early in 1995, was to stably induce caveolae formation in cells not expressing caveolin and lacking caveolae. However, we found that the caveolin-transfected cells grew very slowly and formed fewer and smaller colonies than the mock transfectants. Similar reports were emerging from other laboratories (D Harris et al., personal communication) . Thus, it would seem that the caveolin expression and/ or caveolae formation are required to control membrane protein tracking and to further maintain normal cellular phenotypes. The disruption of the caveolin gene should yield insight and a further understanding into the mechanism of this previously unrecognized biological function of caveolin in vesicular transport in relation to cancer development.
Materials and methods
Cell culture and transfection
Early passage normal human mammary epithelial cells were isolated from the reduction mammoplasty as described (Emerson and Wilkinson, 1990; . Human breast cancer cells (MCF7, T47D, ZR75, MDAMB435, MDAMB43, BT20) and immortalized breast epithelial cells (MCF10 and 184B5) were obtained from ATCC. 21MT-1 cells were a generous gift from V Band. An benzo [a] pyrene immortalized mammary epithelial cell line 184B5 was also obtained from ATCC. All breast cell lines were maintained in DFCI-1 complete medium or in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum. For expression studies, normal and tumor cells were cultured in the same medium (DFCI-1 complete). The human caveolin cDNA was introduced into an eukaryotic expression plasmid, pcDNA3 (Invitrogen), and used for transfection experiments. 25 ± 40% con¯uent breast cancer cells (T47D) were grown in 60 mm Petri dishes, and a total of 5 mg of DNA and lipofectin (15 ml/dish) (GIBCO BRL) were used for transfections. G418 (0.8 mg/ml) selection began 48 h after transfection.
DNA and RNA analysis
Total RNA was extracted from exponentially growing cells. For Northern blot analysis, total RNA (20 mg/lane) was denatured, electrophoresed through 1% agaroseformaldehyde gels, transferred to a nylon membrane, and hybridized as previously described (Lee, 1996) . A human caveolin-1 cDNA clone was isolated by RT ± PCR reactions using caveolin sequence-speci®c primers (Glenny, 1992) . A partial PCR product of approximately 300 bp in size was sequenced and used as a probe to obtain the full-length clone by screening a cDNA library prepared from NMECs (76N) Lee et al., 1992) . Approximately 10 5 recombinant phages (2 ± 4610 3 per 150 mm dish) were transferred in duplicate to nitrocellulose ®lters, and hybridized for overnight at high stringency conditions. The longest cDNA clones from library screening were further characterized. Probes were labeled by 32 P randompriming. Poly(A) + RNA was puri®ed by oligo(dT) cellulose chromatography. cDNA was synthesized with Superscript reverse transcriptase (Gibco BRL) according to the vendor's instructions. The probe 36B4 was used as a loading control. Progressive unidirectional deletions of the human caveolin-1 full-length cDNA clones were generated using exonuclease III (Erase-A-base System; Promega). The original cDNA clones and the deleted derivatives were sequenced by the dideoxy termination sequencing method (Sequenase kit version 2.0; US Biochemical). Southern blot analysis was performed as previously described (Lee et al., 1992) .
Protein analysis and immuno¯uorescence microscopy
Expression of caveolin-1 protein in human mammary epithelial cells including transfected cells was detected using Western blot analysis as previously described (Schnitzer et al., 1995a,b) . Antibodies to caveolin (C13630, Transduction Inc.), cdc2 (Santa Cruz #054), p53 (Oncogene Research; AB-1 for mouse cells; AB-6 for human cells), and b-actin (Sigma) were used for Western blot analysis. For immuno¯uorescence staining with caveolin antibodies, cells were grown in culture on gelatin-coated coverslips as in studies reported earlier (Schnitzer et al., 1995b) , and then washed and ®xed in acetone (7208C for 5 min). After washing in PBS three times, 10 min) and blocking with 2% goat serum in PBS, the cells were incubated with primary antibodies (1:500 dilution), washed, and incubated for 1 h with goat antimouse IgG conjugated to BODIPY FL. After being washed, the coverslips were mounted onto slides for photography set for appropriate¯uorophore excitationemission viewing and storage.
Cell synchronization of NMECs
Cells were plated in 24-well dishes and in 150 mm plates at 7.0610 3 cells/cm 2 . For all conditions the volume of media used was 1.5 ml/well of Zywell dishes and 25 ml/150 mm plates. Synchronization by growth factor deprivation was performed as described (Keyomarsi et al., 1991) . Brie¯y, 36 ± 48 h after plating, cells were washed, incubated in DFCI-3 medium (Keyomarsi et al., 1991) (DFCI-1 medium omitting fetal bovine serum, bovine pituitary extract, cholera toxin, triiodothyronine, insulin, hydrocortisone, and epidermal growth factor) for another 48 h. Under these conditions, cells become quiescent (G 0 ) as determined by lack of Ki-67 antibody staining and [ 3 H]thymidine incorporation. At the time 0, cells were stimulated by the addition of DFCI-1 complete medium. DNA synthesis rate was estimated by measuring the incorporation of [ 3 H]thymidine.
Growth curves and soft agar clonogenic assay
Stable transfectants or control cells (10 4 cells each) were plated in 35 mm tissue culture dishes in triplicate and incubated at 378C for 9 days. Every other day, one set of each culture dishes was trypsinized, and the cell numbers per dish were measured by Coulter counting and also using a hemocytometer. For soft agar assays, cells were plated at a density of 1610 4 in 35 mm tissue culture plates containing 0.33% top low-melt agarose/0.6% bottom low-melt agarose. Foci or colonies were counted and measured after 2 weeks.
Mouse embryonic ®broblast isolation from p53 null mice
Dermal ®broblasts from embryonic day 17 (E17) mouse embryos were isolated from 129/Sv (wild type) or 129 trp53 tmlTyj (p53 knockout-Jackson Labs) mice as previously described (Harvey et al., 1994) . Brie¯y, pregnant females were killed by cervical dislocation, E17 embryos were removed, and the dermis was dissected and placed epidermis side down onto tissue culture-treated plastic for 30 min. DMEM containing 10% FBS was then added to the dish, and the skin was cultured at 378C, 5% C0 2 for several days. Dermal ®broblast which grew out from the skin explants were harvested (0.25% trypsin/0.02% EDTA), expanded, and used within ®ve passages.
Mitomycin C treatment
Cells were plated in six well tissue culture treated dishes and grown to 80% con¯uence. Mitomycin C (Sigma) was added to cultures at 20 mg/ml, and cells were harvested after initiation of treatment at times points over 24 h. All cells were collected and processed for SDS ± PAGE and Western analysis as above.
